Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the Bank of America Securities 2023 Health Care Conference. This event is set for May 9, 2023, at 10:00 a.m. (PT), held at the Encore Hotel in Las Vegas, Nevada. Attendees can access a live audio webcast of the presentation on the Teleflex investor website.
Teleflex specializes in medical technologies aimed at enhancing health and quality of life, offering solutions in vascular access, cardiology, anesthesia, and more. Their innovative approaches address critical clinical needs, benefiting patients and healthcare professionals alike.
Teleflex (NYSE: TFX) will host a conference call on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter financial results and operational updates. Participants can pre-register using the provided link to receive dial-in information. The call will be available via audio webcast on the Teleflex website, and a replay will be accessible after 11:00 a.m. ET on the same day. Teleflex is a global leader in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, anesthesia, and surgical solutions. For further information, stakeholders can visit Teleflex's official website.
Teleflex Incorporated (NYSE: TFX) has announced a supply agreement with W. L. Gore & Associates to integrate GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement into its Titan SGS® Powered Stapling Device for bariatric surgery. This partnership aims to enhance surgical outcomes by combining the advanced technology of the Titan device, specifically designed for sleeve gastrectomy, with Gore's proven staple line reinforcement material. The Titan SGS® offers significant advantages, including reducing stapling time by half and providing a consistent gastric sleeve anatomy. The collaboration highlights both companies' commitment to innovation in the bariatric surgery space.
Teleflex (NYSE: TFX) presented significant findings regarding the UroLift® System for treating benign prostatic hyperplasia (BPH) at the 38th Annual European Association of Urology Congress. Research from over 330 controlled subjects indicates that the UroLift® offers durable results at one and five years, with lower durability linked to undertreatment. Early intervention positively affects quality of life and sexual function. Notably, UroLift® demonstrated a lower complication rate compared to traditional surgeries like TURP. The studies reinforce UroLift® as a leading minimally invasive treatment for BPH, emphasizing its safety and effectiveness.
Teleflex is set to present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:00 p.m. (ET). Thomas Powell, the Executive Vice President and Chief Financial Officer, will deliver the presentation. A live audio webcast will be accessible on the Teleflex investor website. Teleflex, traded as TFX on NYSE, specializes in medical technologies aimed at enhancing health and quality of life, offering solutions across various fields including vascular access, anesthesia, and surgical care. For more details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2023. Shareholders of record as of March 3, 2023 will receive this dividend. Teleflex is dedicated to delivering innovative medical technologies aimed at enhancing healthcare quality and outcomes. Their product range spans multiple sectors, including vascular access, interventional cardiology, and anesthesia. This dividend declaration reflects the company's commitment to returning value to its shareholders while supporting ongoing business growth.
Teleflex Incorporated (NYSE: TFX) reported its Q4 2022 financial results, with revenues of $758.0 million, a slight decline of 0.5% year-over-year, but a 3.7% rise on a constant currency basis. GAAP diluted EPS decreased to $1.65 from $2.69 in Q4 2021. For full year 2022, revenues were $2,791.0 million, down 0.7%, with a GAAP diluted EPS of $7.67, compared to $10.23 in 2021. Looking ahead, Teleflex expects revenue growth of 4.25% to 5.75% for 2023, and GAAP EPS guidance of $8.26 to $8.86. The company emphasizes its commitment to durable growth amidst challenges.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
